Cite

HARVARD Citation

    Almas, S. et al. (n.d.). P647 Outcomes following the use of vedolizumab first line versus second line in Ulcerative Colitis: a single centre experience. Journal of Crohn's and colitis. p. i777. [Online]. 
  
Back to record